VivoSim Labs, Inc. filed a Form 10-Q with the SEC on November 12, 2026, reporting unaudited financial results for the quarterly and six-month periods ended September 30, 2026.

Key Highlights

  • Net loss of $1.813 million for the six months ended September 30, 2026, compared to a net loss of $5.388 million in the same period a year earlier, according to the filing.
  • $5.0 million milestone payment recognized as a gain on milestone payment related to the sale of an asset, recorded in both the three- and six-month periods ended September 30, 2026.
  • Total revenues of $69 thousand for the six months ended September 30, 2026, up from $65 thousand in the prior-year period, comprising service revenue of $22 thousand and royalty revenue of $47 thousand.
  • Cash and cash equivalents of $8.564 million as of September 30, 2026, compared to $5.024 million at March 31, 2026.
  • Common stock warrant liabilities eliminated, declining from $5.700 million at March 31, 2026 to zero at September 30, 2026, following exercise of common warrants generating $6.513 million in proceeds.
  • Shares outstanding increased from 2,894,519 at March 31, 2026 to 18,067,495 at September 30, 2026, primarily reflecting exercises of pre-funded and common warrants and a private placement.
  • Total stockholders' equity turned positive at $7.242 million as of September 30, 2026, compared to a deficit of $1.099 million at March 31, 2026.

VivoSim Labs Financial Results for the Six Months Ended September 30, 2026

According to the filing, VivoSim Labs (NASDAQ:VIVS) reported a net loss of $475 thousand for the three months ended September 30, 2026, and a net loss of $1.813 million for the six-month period. Both figures represent a significant improvement from the prior-year periods, when the company reported net losses of $2.545 million and $5.388 million for the respective three- and six-month periods ended September 30, 2025. The company reported total costs and expenses of $6.144 million for the six months ended September 30, 2026, compared to $5.615 million in the prior-year period, driven by research and development expenses of $2.228 million and selling, general and administrative expenses of $3.860 million.

A notable item in the period, as disclosed in the filing, was a $5.0 million gain on milestone payment related to the sale of an asset, recorded under other income. This was partially offset by a loss on change in fair value of common stock warrant liabilities of $813 thousand for the six months ended September 30, 2026. Net cash used in operating activities was $5.691 million for the six-month period, while net cash provided by investing activities was $5.929 million, the latter including $5.0 million in proceeds from the milestone payment and $1.014 million from the release of an escrow receivable.

The company's balance sheet reflected total assets of $9.924 million as of September 30, 2026, up from $7.386 million at March 31, 2026. The accumulated deficit stood at $357.813 million as of September 30, 2026. The filing states that as of November 1, 2026, a total of 20,281,495 shares of common stock, $0.001 par value, were outstanding. The registrant identified itself as a non-accelerated filer and smaller reporting company.

What Was Disclosed

VivoSim Labs filed its quarterly report covering the period ended September 30, 2026, disclosing a net loss of $1.813 million for the six-month period, a $5.0 million milestone payment gain, and a shift from stockholders' deficit to positive equity of $7.242 million.